Viper Announces Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 22, 2015) -

NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

Viper Gold Ltd. ("Viper" or the "Company") (NEX:VPR.H) is pleased to announce that the Company is proposing a non-brokered private placement ("Private Placement") of up to 5,000,000 units ("Units") of the Company at $0.05 per Unit for gross proceeds of up to $250,000. Each Unit will be comprised of one common share in the capital of the Company ("Share") and one Share purchase warrant ("Warrant"), with each Warrant entitling the holder to purchase one Share at an exercise price of $0.05 for 12 months from closing. Completion of the Private Placement is subject to acceptance by the NEX board of the TSX Venture Exchange (the "Exchange").

The Company intends to use proceeds of the Private Placement for working capital purposes and to investigate business opportunities in the pharmaceutical and technology sectors, areas in which the new management team has experience and expertise.

In connection with the Private Placement, the Company may pay certain finders (the "Finders") a cash commission equal to 8% of the proceeds raised from the subscribers identified by such Finders and issue Finder's compensation warrants (the "Finder's Warrants") equal to 8% of the number of Units sold to such subscribers. The Shares, Warrants and Finder's Warrants will be subject to resale restrictions under applicable law.

Further Information

For further information relating to the Company or this release please visit www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer of the securities of the Company for sale in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, (the "1933 Act") as amended, and may not be offered or sold within the United States absent registration or an exemption from registration under the 1933 Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Cautionary and Forward-Looking Statements

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the proposed private placement including the potential proceeds and completion thereof as well as the Company's corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to complete the private placement on acceptable terms or at all. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth as well as risks associated with the pharmaceutical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; commodity price and exchange rate fluctuations; marketing and commercialization; loss of markets; competition; incorrect assessment of the value of technologies acquired and failure to realize the anticipated benefits of such acquisitions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and Health Canada regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.